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Abstract
Seeding and spread of beta-amyloid (Aβ) pathologies have been considered to be based on prion-like mechanisms.
However, limited transmissibility of Aβ seeding activity upon peripheral exposure would represent a key difference to
prions, not only in terms of pathogenesis but also in terms of potential transmission of disease. We partially characterized
the seeded Aβ amyloidosis after intracerebral injection of various brain homogenates in APP/PS1 mice. One particularly
seed-laden homogenate was selected to investigate the development of Aβ pathologies after intravenous exposure. We
report here that a single intravenous injection of an Alzheimer disease patient’s-brain extract into APP/PS1 recipient mice
led to cerebral amyloid angiopathy within 180 days post injection. Thus, vascular proteinopathies such as CAA are
transmissible in mice via the intravenous route of peripheral exposure.
Introduction
Intracerebral injections of beta-amyloid (Aβ) require
femtogram quantities of brain-derived Aβ seeds to
induce an Alzheimer’s disease (AD)-like pathology in
amyloid precursor protein (APP)-transgenic APP23 or
tg2576 mice [7, 14, 18, 19]. This process has been
considered to be comparable to intracerebral infections
with “classical” prions consisting of the misfolded prion
protein (PrPSc). The apparent ease of intracerebral trans-
mission suggests that the seeding and spread of Aβ path-
ologies in brain tissue may - at least in part - occur in a
manner similar to PrPSc-based prions [2, 13]. Unlike
prion transmissibility however, oral, intraocular, intrana-
sal, and intravenous administration of Aβ seeds did not
promote development of AD-like pathologies in APP23
transgenic mice. Only administrations of Aβ seeds via
the intraperitoneal route were sufficient to induce a
cerebral Aβ amyloidosis in this AD mouse model [8].
Interestingly, intravenous transmission of scrapie disease
in mice is far more efficient than the intraperitoneal
route of infection and is almost as potent as direct intra-
cerebral injection [15]. Overall, limited transmissibility
of Aβ seeding activity via peripheral exposure would
represent a key difference to prions, not only in terms of
pathogenesis but also in terms of potential transmission
of disease.
To our knowledge the intravenous transmission of
AD-like pathologies by Aβ seeds was so far only
attempted in one experimental setting using trans-
genic APP23 mice as recipients and APP23-mouse
brain-derived homogenate as Aβ seed-containing in-
oculates [6]. A separate study used synthetic Aβ pep-
tides but the actual route of exposure was
questionable [16]. To study Aβ seeding activity fol-
lowing intracerebral and intravenous administrations
we decided to employ APPSwe/PS1dE9 mice (here
termed APP/PS1 mice) as hosts.
Methods
Animals
The study was approved by the local animal welfare
authority (Landesamt für Gesundheit und Soziales,
Berlin, Germany). APP/PS1 mice backcrossed to C57BL/
6 were obtained from The Jackson Laboratory. Further
breeding was done by pairings with non-transgenic
C57BL/6 wildtype mice to keep the line heterozygous.
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Brain tissue extracts
Mice brain extracts were derived from aged (15- to 18-
month-old) APP/PS1 mice (termed APP) and age-
matched non-transgenic, control C57Bl/6 mice (termed
B6). Males and females were used but care was taken to
keep gender ratios close to 50% (overall 52% males, 48%
females). For the results presented in Fig. 2f the two
small groups with n = 3 consisted of two males and one
female each. Human brain extracts were derived from
the frontal cortices of two 64 and 68 years old AD
patients (termed AD1 and AD2) and from a 48-year-old
non-demented control patient (termed HCT). Both AD
patients were categorized as CERAD neuritic plaque
score C and Braak tangle stage VI; the non-demented
control was CERAD 0. Tissues were homogenized at
10% (wt/vol) in PBS, vortexed, sonicated for 5 s, and
centrifuged at 3000 g for 5 min. Supernatant were then
aliquoted and stored at − 70 °C. Western-blot analysis
showed equal amounts of Aβ in patients AD1 and AD2
extracts, whereas no Aβ was detected in the HCT
sample. The APP/PS1 mouse-derived extract contained
at least 5 times more Aβ per ng total protein than the
AD patients extracts (data not shown).
Intracerebral and intravenous injections
Intracerebral injections (20 μl of 10% brain homoge-
nates) were applied in the sagittal midline. Intravenous
injections were performed by slowly applying a total
volume of 60 μl of 10% brain extracts further diluted
(1:3 v/v) in sterile isotonic saline into the tail veins.
Tissue collection
Mice were killed with an overdose of isoflurane and
transcardially perfused with ice-cold PBS. Subsequently,
brains were removed and divided sagitally. Brains were
fixed in paraformaldehyde (4% for 24 h and 2% for add-
itional 2–14 days) at 4 °C followed by dehydration and
embedding in paraffin. Time points of sacrifice were
360 days post injection for intracerebral challenge and 180
and 270 days post injection for the intravenous exposure.
Histological studies
Aβ deposits were detected using anti-Abeta 4G8 antibody
(SIG-39220; BioLegend) as described previously [17].
Double-stainings to confirm vascular amyloid deposition
were done using the amyloid-specific luminescent-
conjugated pentameric thiophen pFTAA [1] and the anti–
alpha smooth muscle actin 1A4 antibody-Alexa Fluor 594
conjugate (ab202368, Abcam). The extent of the CAA was
quantified by counting amyloid-positive blood vessels in
thalami, cortices, as well as the cortically attached lepto-
meninges in at least 3 separate (120 μm apart) sections
per mouse brain. The obtained numbers of Aβ-positive
vessels per area were then taken for statistical analysis.
Plaque loads were similarly determined in hippocampi
and cortices.
Statistical analysis
All data were analyzed using Prism 5 software (GraphPad
Software Inc.). Statistical differences between groups were
assessed using the two-tailed Mann-Whitney U test or, in
case of small group sizes, the Kruskal-Wallis test and
Dunn’s multiple comparison test.
Results and discussion
To demonstrate the development of an Aβ amyloidosis
triggered by intracerebral exposure to Aβ seeds in our
system, we injected various brain homogenates intrace-
rebrally into 6–8 weeks old APP/PS1 mice.
Three hundred sixty days post intracerebral injection
cortices and hippocampi of all APP/PS1 mice were, as
expected for this mouse line at an age of 13.5–
14 months, loaded with amyloid plaques regardless of
the source of the injected brain homogenate (data not
shown). However, in particular the AD1- and AD2-
injected mice showed a pronounced vascular amyloid
deposition affecting multiple small vessels in the thal-
amus region, which was not seen upon injection of the
negative control extracts (Fig. 1). Of note, beginning at
an age of about 6 months, APP/PS1 mice develop a pro-
gressive cerebral amyloid angiopathy typically assigned
to the leptomeninges, while CAA in the thalamic region
has not been described so far [9]. This is in line with our
findings in untreated APP/PS1 mice, in which up to an
age of 14 months thalamic CAA is not a prominent
feature (Fig. 1e and Fig. 2e, f ).
To test transmissibility of an Aβ amyloidosis following
intravenous exposure single injections of diluted brain
extracts AD1 and HCT into the tail veins of 6–8 weeks
old APP/PS1 mice were carried out. The first time point
of analysis was 180 dpi when the mice were 7.5–
8 months old. Most strikingly, a significantly higher
number of Aβ-decorated blood vessels was evident in
the thalamus areas of the AD1 group in comparison to
control-injected and to untreated mice (Fig. 2). Essen-
tially the same observations were made at a later time
point, namely at 270 dpi. Just like before, the thalamic
CAA was clearly more pronounced in the AD1-injected
group compared to the controls (Fig. 2f ). Double-
stainings with amyloid-binding compound pFTAA and
anti-smooth muscle actin antibody 1A4 additionally
confirmed the deposition of Aβ in the thalamic vascula-
ture (Fig. 3).
Furthermore, we also observed significant increased
CAA in cortices and attached leptomeninges upon intra-
venous injection of the AD1 extract compared to the
controls (Fig. 4). However, at both time points, 180 and
270 dpi, neither hippocampal nor cortical amyloid plaque
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loads seemed to be affected by the intravenously applied
exposure to Aβ seeds (Table 1).
Our results demonstrate for the first time that intra-
venously administered Aβ seeds of human origin pro-
mote vascular Aβ deposition in APP/PS1 mice. In APP/
PS1 mice the transgenes are, due to the employed Prnp
promoter, also expressed in the periphery, which is not
the case in APP23 mice, in which the expression of the
transgene is confined to neurons of the CNS [11, 22].
Thus, in APP/PS1 mice interaction of injected Aβ seeds
with already present peripheral human Aβ may support
the transport of seeds towards the brain.
Interestingly, the amyloidosis occurring after intraperi-
toneal administration of Aβ seeds was also seen to be
predominantly associated with blood vessels [8]. Of note,
the AD patient-derived brain extracts triggered a consid-
erably more pronounced thalamic CAA than the APP/
PS1 mouse brain-derived inoculum (Fig. 1e). “Strain”-
like properties of Aβ seeds or Aβ aggregates have been
suggested to play a role in the pathogenesis of distinct
AD phenotypes [4, 10, 20]. Likewise, Aβ pathologies
may vary upon transmission depending on the charac-





Fig. 1 Vascular amyloid deposition following intracerebral injection of brain extracts into APP/PS1 mice. Aβ deposits were detected 360 days post
injection using the 4G8 monoclonal antibody. a Representative overview of the hippocampus and thalamus regions upon injection of the negative
control homogenate HCT. b Hippocampus and thalamus regions after injection of AD1 homogenate. Scale bar 500 μm. c, d Examples of thalamic CAA
after injection of the AD1 extract at higher magnifications. The majority of Aβ deposits in the thalamus is vascular. Scale bars 25 μm in (c) and 12.5 μm in
(d). e Quantification of thalamic CAA 360 days after intracerebral injection of brain extracts. Indicated is the mean ± SEM. Mann-Whitney U test, group
sizes n= 5 (HCT), n= 6 (B6), n = 6 (APP), n= 7 (AD1), and n= 7 (AD2). P= 0.003 for B6 versus AD1 and AD2; p = 0.0085 B6 versus APP, p = 0.38 B6 versus
HCT, p = 0.1026 for AD1 versus AD2. Of note, the CAA in AD patients extracts AD1- and AD2-injected mice was significantly more pronounced than in
mice receiving the APP/PS1 brain homogenate; p = 0.0264 and p = 0.0052 for AD1 and AD2 versus APP, respectively




Fig. 2 CAA following intravenous injection of brain extracts into APP/PS1 mice. a Representative overview of the hippocampus and thalamus regions
upon injection of the negative control homogenate HCT. b Hippocampus and thalamus regions after injection of AD patient homogenate AD1, 180 days
post injection. Scale bar 500 μm. c Example of thalamic CAA after injection of the AD1 extract at higher magnification. The majority of Aβ deposits in the
thalamus is vascular. Scale bar 25 μm. d Thalamic CAA with notable spread of Aβ deposition into the adjacent tissue after injection of the AD1 extract.
Scale bar 12.5 μm. e Quantification of thalamic CAA 180 days after intravenous injection of brain extracts. Untreated APP/PS1 mice of the same age, which
did not receive any injections, were included for additional comparison. Indicated is the mean ± SEM. Mann-Whitney U test, group sizes n= 6 (AD1), n= 6
(HCT) and n= 7 (untreated). P= 0.008 and p= 0.0062 for AD1 versus HCT and the untreated group of mice, respectively. f Quantification of thalamic CAA
270 days after intravenous injection of brain extracts. Indicated is the mean ± SEM. Kruskal-Wallis test, group sizes n = 3 (AD1), n = 3 (HCT)




Fig. 3 Double-stainings with amyloid-binding compound pFTAA and anti-smooth muscle actin antibody 1A4 to demonstrate the vascular Aβ deposition
in thalami of intravenously AD1 injected mice. a, d staining with pFTAA; b, e staining of the same section with 1A4 antibody; c, f overlay of the pFTAA
(green)/1A4 (red) stains. Scale bar 12.5 mm
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In summary, we report here that intravenous injec-
tion of Aβ seeds derived from human AD brain ex-
tract promoted a vascular Aβ amyloidosis in APP/PS1
mice. Our data add novel aspects to the ongoing
discussion on the transmissibility of proteinopathies
such as prion diseases and AD [13]. There are to date
no data allowing to conclude that Aβ seeding activity
is transmissible via blood or blood products [5]. How-
ever, at least in mice blood-derived Aβ can pass the
blood-brain barrier to form amyloid deposits in the
brain [3]. Moreover, observational evidence suggests
that Aβ pathologies were transmitted by repeated
intramuscular injections of cadaveric-derived, human
growth hormone preparations [12, 21]. Thus, further
research is required to identify the factors contributing to
transmissibility of misfolded proteins and ultimately
to prevent transmission of amyloid pathologies in
humans.
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